Navigation Links
Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
Date:3/19/2008

AMSTERDAM, March 20 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that AMT's Supervisory Board has decided to propose Alexander Ribbink to be appointed to the Supervisory Board at its Annual General Meeting of shareholders on April 16, 2008. Mr. Ribbink is Chief Operating Officer of TomTom (Euronext Amsterdam: TOM2), and has been instrumental in building TomTom into the world's largest portable navigation solutions provider.

Mr. Ribbink, who joined TomTom in 2003, spent 11 years with Unilever, specializing in consumer marketing and general management, becoming vice-president for brand development for one of the company's largest Dutch food subsidiaries. He later managed a key European business unit for Mars, Inc.

Further to a plan of rotation that aims to build a fully independent Supervisory Board in the course of 2008, AMT expects to propose several other independent candidates to replace current non-independent members. Earlier this year, AMT announced the nomination of Mr. Philippe van Holle, Head of Celgene Europe (NASDAQ: CELG), to its Supervisory Board.

AMT's AGM is scheduled for April 16, 10:30 a.m., and will take place at the Rosarium, Amsterdam, The Netherlands.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases that are caused by one faulty gene. AMT currently has a product pipeline with six products at different stages of development.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business, including, but not limited to, the timely commencement and success of AMT's clinical trials and research endeavors, delays in receiving U.S. Food and Drug Administration or other regulatory approvals (i.e. EMEA, Health Canada), market acceptance of AMT's products, effectiveness of AMT's marketing and sales efforts, development of competing therapies and/or technologies, the terms of any future strategic alliances, the need for additional capital, the inability to obtain, or meet, conditions imposed for required governmental and regulatory approvals and consents. AMT expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting AMT, refer to the prospectus of AMT's initial public offering on June 20, 2007, and AMT's public announcements made from time to time.


'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
2. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
4. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
5. Society for Biomolecular Sciences Announces 2008 Conference Speaker Line-up
6. WaferGen to Present at the Cambridge Health Institutes Fifth Annual Molecular Diagnostics Partnerships in Personalized Medicine Conference
7. NIST team proves bridge from conventional to molecular electronics possible
8. AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc. for Molecular Quality Control Standards
9. Center for Molecular Medicine Partners with AviaraDx to Offer New Cancer Tests to Aid Physicians in Personalizing Treatment
10. Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer
11. Molecular Diagnostics Leader AdvanDx Taps Former Dako Executive Vice President to Lead Global Sales and Marketing Expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... /PRNewswire/ - Last year,s petition to the White House signed ... active to generate awareness on the importance of new organic medicines ... healthcare market place. ... Earlier this month Health Advance (OTC PINK: ... nutritional products, announced its endeavors on this generally recognized as ...
(Date:3/29/2017)... , March 29, 2017  Applied BioMath ... mechanistic modeling to drug research and development, ... with Zymeworks Inc. for quantitative systems pharmacology ... intended for the treatment of cancer. ... previously for GLP toxicology studies and first-in-human ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... Bactana Animal ... hormones in the world’s food supply through enhancement of the gut microbiota, today announced ... included Connecticut Innovations , New York-based Sustainable Income Capital Management, LLC and a ...
(Date:3/29/2017)... -- Research and Markets has announced the addition ... report to their offering. ... The study scope includes key ... interference, synthetic biology tools and genome editing tools); synthetic biology-enabled ... technologies and products are analyzed to determine present and future ...
Breaking Biology Technology:
(Date:3/7/2017)... 7, 2017 Brandwatch , the leading social intelligence ... Prince,s Trust to uncover insights to support its reporting, help ... The UK,s leading youth charity will be using Brandwatch Analytics ... get a better understanding of the topics and issues that are ... ...
(Date:3/2/2017)... LONDON , March 2, 2017 Summary ... require to better understand Merck KGaA and its partnering ... report: https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals ... into the partnering activity of one of the world,s ... reports are prepared upon purchase to ensure inclusion of ...
(Date:2/28/2017)... 28, 2017   Acuant , a leading provider ... significant enhancements to new and core technologies building upon ... include mobile and desktop Acuant FRM TM facial ... a real time manual review of identity documents by ... the fastest and most accurate capture software to streamline ...
Breaking Biology News(10 mins):